Old Web
English
Sign In
Acemap
>
authorDetail
>
L. Akella
L. Akella
Medicine
Placebo
Internal medicine
Arginase
double blind
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
529: A phase 1b, randomized, double-blind, placebo-controlled, dose-escalation trial of CB-280, an arginase inhibitor, in patients with cystic fibrosis
2021
Journal of Cystic Fibrosis
S. Boas
S. Donaldson
K. McBennett
T Liou
J. Howrylak
L. Johnson
C. Teneback
A. Dozor
G. Sawicki
J. Dumlao
A. Pan
L. Akella
J. Zhang
S. Carroll
K Orford
E. Kuriakose
J. Mermis
Show All
Source
Cite
Save
Citations (0)
P47.07 KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC
2021
Journal of Thoracic Oncology
David R. Spigel
Wallace Akerley
M. Evangelist
Melissa Lynne Johnson
Benjamin Levy
Taofeek K. Owonikoko
Paul K. Paik
Thales Papagiannakopoulos
Karen L. Reckamp
L. Akella
S. Holland
Y. Jenkins
E. Kuriakose
Naiyer A. Rizvi
Show All
Source
Cite
Save
Citations (0)
1